Evidence map›Paper›PMID 42098254›Full record

ArticleCommunications chemistry2026

Dual-LAO for calculating fast and robust relative binding free energies of simple and complex transformations.

Narjes Ansari, Félix Aviat, Jérôme Hénin, Jean-Philip Piquemal, Louis Lagardère

Abstract read
In one paragraph

Article in Communications chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Narjes Ansari *Qubit Pharmaceuticals, Advanced Research Department, Paris, France. narjesa@qubit-pharmaceuticals.com.ORCID http://orcid.org/0000-0003-2017-8431
Félix Aviat *Qubit Pharmaceuticals, Advanced Research Department, Paris, France. felix.aviat@qubit-pharmaceuticals.com.ORCID http://orcid.org/0009-0005-8134-8715
Jérôme HéninLaboratoire de Biochimie Théorique, UPR 9080 CNRS, Université de Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-2540-4098
Jean-Philip PiquemalQubit Pharmaceuticals, Advanced Research Department, Paris, France.
Louis LagardèreQubit Pharmaceuticals, Advanced Research Department, Paris, France. louis.lagardere@sorbonne-universite.fr.ORCID http://orcid.org/0000-0002-7251-0910

Funding

Grand Équipement National De Calcul Intensif (GENCI) AD010716167R1
6 · The paper itself

Abstract

Relative binding free energy (RBFE) calculations are a cornerstone of rational hit-to-lead and lead optimization in modern drug discovery. However, the high computational cost and limited reliability in tackling large or complex molecular transformations often prevent their routine, high-throughput use. Here we introduce Dual-LAO, a novel, highly efficient method for calculating RBFE. Building on the Lambda-ABF-OPES framework, this method combines a dual-topology setup and suitable restraints to dramatically accelerate free energy convergence. We demonstrate that Dual-LAO, in combination with the AMOEBA polarizable force field, achieves an unprecedented acceleration factor of 15 to 30 times compared to current state-of-the-art methods on standard drug targets. Crucially, the approach maintains high accuracy and successfully tackles previously prohibitive molecular changes, including scaffold-hopping, buried water displacement, charge changes, ring-opening, and binding pose perturbations. This significant leap in efficiency allows for the widespread, routine integration of predictive molecular simulations into the rapid optimization cycles of drug discovery, enabling chemists to confidently model historically challenging systems in timescales compatible with real-world project deadlines.

Identifiers

PMID42098254
PMCPMC13369361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.